KalVista Q3 2024 Earnings Report
Key Takeaways
KalVista Pharmaceuticals reported its third fiscal quarter results with key highlights including positive topline data from the Phase 3 KONFIDENT clinical trial and the completion of an underwritten offering that yielded approximately $150.1 million in net proceeds.
Phase 3 KONFIDENT clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile.
Closed an underwritten offering with net proceeds of approximately $150.1 million, expected to provide funding into 2026.
Benjamin L. Palleiko was appointed as Chief Executive Officer.
The UK MHRA awarded the Innovation Passport for sebetralstat.
KalVista
KalVista
Forward Guidance
KalVista anticipates submitting a new drug application to the U.S. Food and Drug Administration (FDA) for sebetralstat in the first half of 2024 and expects to file for approval in Europe and Japan later in 2024.